Timing of Smoking Intervention in Alcohol Treatment (Nicotine Patch)

NCT ID: NCT00000444

Last Updated: 2011-02-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

1997-09-30

Study Completion Date

2004-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will attempt to determine the best time to begin a smoking cessation program in individuals who undergo intensive treatment for alcohol dependence. The goal of this trial is to determine whether a smoking cessation program is more effective if it occurs at the same time as or after treatment for alcohol dependence. The study also will attempt to determine the effect of smoking cessation programs on the outcome of treatment for alcohol dependence.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcoholism Smoking

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nicotine replacement patch

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meets criteria for alcohol use disorder and other drug dependence.
* Complete first week of alcohol treatment program.
* Current cigarette smoker (more than 5 cigarettes/day, smoking more than 1 year).

Exclusion Criteria

* Lifetime diagnosis of an excluding psychiatric disorder: bipolar disorder, schizophrenia or other psychotic disorder, panic disorder with or without agoraphobia, obsessive-compulsive disorder, generalized anxiety disorder, eating disorder, post- traumatic stress disorder, antisocial personality disorder, or borderline personality disorder.
* Unable to participate in protocol due to functional deficits or severe depression.
* Suicidal or homicidal ideation.
* Current use of disulfiram (Antabuse) or naltrexone (Revia).
* Current use of pipes, cigars, or smokeless tobacco and unwillingness to stop.
* Lives more than 100 miles from alcohol treatment facility.
* No telephone.
Minimum Eligible Age

21 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

Sponsor Role collaborator

Minneapolis Veterans Affairs Medical Center

FED

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

General Internal Medicine, VA Medical Center

Minneapolis, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01AA011124

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NIAAAJOS11124

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Non-Nicotine Agents for Smoking Cessation
NCT00108537 COMPLETED PHASE3
Varenicline in Drug Treatment
NCT01286584 COMPLETED PHASE4